Invention Grant
- Patent Title: Heterocyclic compound
-
Application No.: US16961476Application Date: 2019-01-30
-
Publication No.: US11459325B2Publication Date: 2022-10-04
- Inventor: Yuta Tanaka , Tomohiro Ohashi , Zenichi Ikeda , Yuta Tanaka , Florian Pünner , Takeshi Yamamoto , Keiko Kakegawa , Fumiaki Kikuchi , Nao Morishita , Takahito Kasahara , Masaki Seto , Minoru Nakamura , Kazuaki Takami , Masataka Murakami , Masaki Daini , Satoshi Mikami , Minoru Sasaki
- Applicant: Takeda Pharmaceutical Company Limited
- Applicant Address: JP Osaka
- Assignee: Takeda Pharmaceutical Company Limited
- Current Assignee: Takeda Pharmaceutical Company Limited
- Current Assignee Address: JP Osaka
- Agency: Foley & Lardner LLP
- Priority: JP2018-015264 20180131
- International Application: PCT/JP2019/003044 WO 20190130
- International Announcement: WO2019/151269 WO 20190808
- Main IPC: C07D471/04
- IPC: C07D471/04 ; C07D487/04 ; C07D491/048 ; C07D495/04 ; C07D519/00 ; A61P25/28

Abstract:
The present invention provides a compound having a glucosylceramide lowering action (e.g., promoting glucosylceramide metabolism, inhibition of glucosylceramide synthesis, promoting glucosylceramide catabolism, etc.), which is expected to be useful as an agent for the prophylaxis or treatment of lysosome diseases (e.g., Gaucher's disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.
Public/Granted literature
- US20210087186A1 HETEROCYCLIC COMPOUND Public/Granted day:2021-03-25
Information query